Transaction Search Form: please type in any of the fields below.
Date: April 30, 2024 Tue
Time: 12:41 am
Time: 12:41 am
Results for prescription medicines
3 results foundAuthor: Rodwell, Laura Title: What Do Police Data Tell Us About Criminal Methods of Obtaining Prescription Drugs? Summary: Recent reports suggest that the illicit use of prescription medicines, particularly pharmaceutical opioids is increasing in Australia. The aim of this study was to use police data to examine: (1) whether this increase is reflected in police crime data; (b) some of the criminal methods by which these medicines are obtained; and (c) which particular medicines have been most commonly sought through these methods over time. Details: Sydney: NSW Bureau of Crime Statistics and Research, 2010. 12p. Source: Internet Resource; Crime and Justice Bulletin, No. 139 Year: 2010 Country: Australia URL: Shelf Number: 118722 Keywords: Drug Abuse and AddictionOpioidsPrescription FraudPrescription Medicines |
Author: Larance, Briony Title: The Diversion and Injection of the Pharmaceutical Opioids Used in Opioid Substitution Treatment: Fidings from the Australian Post-Marketing Surveillance Studies of Buprenorphine-Naloxone, 2006-2008 Summary: Opioid substitution treatment (OST) is effective in treating opioid dependence, and results in significant reductions in the negative health consequences and adverse effects on public order. In Australia, OST is highly regulated: it is available only with an individual patient authority, there is licensing of doctors, and a strong focus on supervised administration of medication. Adherence with OST is important for maximising a range of positive treatment outcomes, but is especially important in preventing injection, "leakage" of prescribed medication to the illicit market, overdose and mortality. The introduction of an opioid agonist-antagonist formulation in Australia was a new approach that was hoped to result in lower levels of injection of the medication. By deterring injection, buprenorphine-naloxone (registered as Suboxone) may reduce its attractiveness in illicit markets. Post-marketing surveillance of the diversion and injection of Suboxone was required as a condition of the product's registration in Australia. Reckitt Benckiser approached the National Drug and Alcohol Research Centre to conduct the study independently, by way of an untied educational grant. 1.1. Terminology Post-marketing surveillance studies are usually observational in design and monitor the safety of new medications being used in real-life applications. Pre-marketing (clinical) studies usually involve detailed protocol constraints and small sample sizes, and although they may suggest which medications are likely (or not likely) to be misused, they are limited in their ability to detect and quantify actual misuse. Diversion is used in this report to describe the unsanctioned supply of regulated pharmaceuticals from legal sources to the illicit drug market, or to a user for whom the drugs were not intended. Adherence is used to describe the taking of medication in accordance with prescription directions and the meeting of all the specified conditions of treatment (e.g. consumption of the dose under supervision, attendance at designated dosing times, meeting requests for urinalysis, etc). Non-adherence is, therefore, any use of a medication by the individual to whom it was prescribed where the medication was not taken exactly as directed. This includes (but is not limited to) removing all or part of a supervised dose from the dosing site for personal use or diversion to illicit markets, splitting doses, stockpiling doses, taking more or less than the prescribed dose, and injection of prescribed medication(s). This report seeks to answer the following questions: (i) Is there injection of the agonist-antagonist formulation - buprenorphine naloxone - following its large-scale introduction into treatment programs for opioid dependence? (ii) To what extent is buprenorphine-naloxone injected compared to existing OST formulations, and in particular compared to the mono-buprenorphine product, among those receiving treatment and among out-of-treatment injecting drug users (IDU)? (iii) Is diverted buprenorphine-naloxone less attractive in illicit markets? (iv) What influences the diversion and/or injection of buprenorphine-naloxone? Details: Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2009. 143p. Source: Internet Resource: Technical Report No. 302: Accessed August 22, 2011 at: http://www.med.unsw.edu.au/NDARCWeb.nsf/resources/TR+298-302/$file/TR+302.pdf Year: 2009 Country: Australia URL: http://www.med.unsw.edu.au/NDARCWeb.nsf/resources/TR+298-302/$file/TR+302.pdf Shelf Number: 122461 Keywords: Drug Abuse and AddictionDrug Abuse TreatmentIllicit DrugsOpioidsPrescription Medicines |
Author: Murphy, Kelly Title: Finding Solutions to the Prescription Opioid and Heroin Crisis: A Road Map for States Summary: Inappropriate opioid prescribing is fueling one of the deadliest drug epidemics in United States history. Every day in the U.S., 78 people die from an opioid-related overdose. In addition to the tragedy of lost lives, states bear many of the financial costs associated with addiction through state-funded health care programs, substance use programs, the criminal justice system and lost productivity. Developed by the NGA Center through extensive consultation with senior state officials and other national experts, the road map is a tool to help states respond to the growing opioid crisis. The road map features a public health approach focused on preventing and treating the disease of opioid use disorder, while strengthening law enforcement efforts to address illegal supply chain activity. It is designed as a policy development tool, allowing a state to use all or portions of the road map as it applies to their unique situation. Details: Washington, DC: National Governor's Association, 2016. 40p. Source: Internet Resource: Accessed July 19, 2016 at: http://www.nga.org/files/live/sites/NGA/files/pdf/2016/1607NGAOpioidRoadMap.pdf Year: 2016 Country: United States URL: http://www.nga.org/files/live/sites/NGA/files/pdf/2016/1607NGAOpioidRoadMap.pdf Shelf Number: 139661 Keywords: Drug Abuse and Addiction Opioids Prescription Fraud Prescription Medicines |